Mobilization of leukemic cells by agents such as plerixafor and GMI-1271 that disrupt cell adhesion mediated by CXCR4 and E-selectin, respectively, can sensitize AML cells to chemotherapy in vivo [8,41]. This evidence concerns the gene CXCR4 and acute myeloid leukemia.